A pill that has been sitting in medicine cabinets for more than a century is showing signs of being far more powerful than anyone originally imagined, as a growing body of clinical evidence points to aspirin as a meaningful weapon against cancer. Researchers at the Karolinska Institute in Sweden tracked nearly 3,000 bowel cancer patients and found that those taking just 160mg of aspirin daily had less than half the risk of cancer recurrence compared to those on a placebo, results so striking that Sweden began screening bowel cancer patients for specific tumor mutations from January 2026 and offering low-dose aspirin to those who test positive. Scientists have identified two distinct biological mechanisms behind this: aspirin reduces inflammation that tumors exploit to grow and spread, and it blocks a clotting factor that suppresses the immune system’s ability to detect and destroy cancer cells, making tumors more visible to the body’s own defenses. Guidelines in the UK were already updated in 2020 to recommend aspirin for people with Lynch Syndrome from around age 20.
Now a much larger trial is underway to find out how far these effects extend. Led by Professor Ruth Langley at University College London, the study involves 11,000 participants across the UK, Ireland, and India who have previously had colorectal, breast, gastroesophageal, or prostate cancer, testing whether a daily low-dose aspirin can prevent recurrence across all four types, with results expected next year. Researchers are careful to note that aspirin carries real risks including internal bleeding and stomach ulcers, and stress that no one should start taking it for cancer prevention without speaking to a doctor first. But for a drug that costs pennies a day and has been in use for more than 125 years, the emerging evidence that it may also be one of the most broadly effective cancer-fighting tools ever discovered is a development the medical world is watching with very considerable excitement.
